euroinflammation in the pathogenesis and progression of Parkinson's disease

Not yet recruiting

• Conditions: Parkinson's disease; 10028037

• Registration Number: NL-OMON30138
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 18 June 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 20

Inclusion Criteria

Inclusion criteria (healthy volunteers)
Age over 40
Informed consent;Inclusion criteria (patients)
-Age over 40
-Informed consent.
-Regarded by the treating physician to have competence of judgement.
-Compliance with the criteria for possible or probable PD as proposed by Gelb, Oliver and Gilman [1999]
-de novo PD without PD medication, or advanced PD with Hoehn and Yahr stage of at least 2.

Exclusion Criteria

Exclusion criteria (all PET-study subjects)
- Prior cardiovascular brain disease, other brain disease (including former traumatic contusion)
- Evidence of any general medical disease, e.g. significant kidney or liver disease, evidence of autoimmune disease.
- Use of anti-inflammatory medication: NSAID*s and steroids.
- Use of benzodiazepines. Benzodiazepines have affinity for the PBR receptor that binds the PET tracer PK11195 and can interfere with the study.
- Abnormalities at clinical neurological examination
- Pregnancy in women of childbearing potential.
- Exposure to a significant amount of radiation in the past year.
- Radiological workers.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Uptake of the radiolabeled PK11195 measured with PET as a measure of activated<br /><br>microglia in neuroinflammation. The groups will be statistically compared using<br /><br>an SPM programme.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>not applicable</p><br>